ClinicalTrials.gg
CompletedNCT03339297Updated Aug 18, 2021Results posted

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

A Phase 2 interventional study of Defibrotide and Standard of Care in Graft-versus-host Disease and Acute-graft-versus-host Disease, sponsored by Jazz Pharmaceuticals. Completed at 62 sites in 14 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2021-08-18.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
28th of 389
152 · median 30
Started
2018
with 14 others
Phase 2
164 of 454
15 open now
Registered
339th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 28th largest by enrollment of the 389 interventional ones that give a count, is one of 15 that started in 2018, is one of 164 in phase 2, and was the 339th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 148 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 41 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

This is a study comparing the defibrotide prophylaxis arm vs standard of care arm for the prevention of aGvHD.

03

Conditions studied

  • Graft-versus-host Disease
  • Acute-graft-versus-host Disease

Browse trials for

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥1 year of age at screening and undergoing Hematopoietic Stem Cell Transplant (HSCT).
  2. Participant must be diagnosed with acute leukemia in morphologic complete remission (CR1 or CR2) or with Myelodysplastic syndrome (MDS) with no circulating blasts and with less than 5% blasts in the bone marrow
  3. Participant must have planned to receive either a myeloablative or reduced-intensity conditioning regimen and have an unrelated donor who is human leukocyte antigen (HLA) matched or single-allele mismatched
  4. Participant must receive the following medical regimen as part of standard of care immunoprophylaxis for GvHD in either study arm at doses and regimen determined by local institutional guidelines, physician preference, and participant need:

    Methotrexate (MTX) or Mycophenolate mofetil (MMF) + calcineurin inhibitor (Cyclosporine A [CSA] or Tacrolimus [TAC]) +/- Anti-thymocyte globulin (ATG) (ATG use is limited to 30% of participants).

  5. Graft must be a CD3+ T-cell replete peripheral blood stem cell (PBSC) graft or non-manipulated bone marrow (BM) graft.
  6. Adult participants must be able to understand and sign a written . For pediatric participants, the parent/legal guardian or representative must be able to understand and sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Participant has had a prior or allogeneic HSCT.
  2. Participant is using or plans to use an agent for the prevention of GvHD.
  3. Participant is receiving or plans to receive other investigational therapy and/or is enrolled or plans to enroll in a separate clinical study.
  4. Participant, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
  5. Participant has a psychiatric illness that would prevent the participant or legal guardian or representative from giving and/or assent.
  6. Participant has a serious active disease or co-morbid medical condition, as judged by the investigator, which would interfere with the conduct of this study.
  7. Participant is pregnant or lactating and does not agree to stop breastfeeding.
  8. Any other condition that would cause a risk to the participant if he/she participated in the trial.
  9. Participant has a known history of to defibrotide or any of the .
  10. Participant had acute bleeding that is within 24 hours before the start of study treatment, defined as either of the following:

    • Hemorrhage requiring >15 cc/kg of packed red blood cells (eg, pediatric participant weighing 20 kg and requiring 300 cc packed red blood cells/24 hours, or an adult weighing >70 kg and requiring 3 units of packed red blood cells/24hours) to replace blood loss, or
    • Bleeding from a site which, in the investigator's opinion, constituted a potential life-threatening source (eg, pulmonary hemorrhage or central nervous system bleeding), irrespective of amount of blood loss
  11. Participant used any medication that increases the risk of bleeding within 24 hours before the start of study treatment, including, but not limited to, systemic heparin, low molecular weight heparin, heparin analogs, alteplase, streptokinase, urokinase, antithrombin III, oral anticoagulants including warfarin, and other agents that increase the risk of bleeding. Participants may have received heparin or other anticoagulants for routine central venous line management and intermittent dialysis or ultrafiltration. Fibrinolytic instillation for central venous line occlusion was also permitted. Note: Heparin used to keep catheters open was allowed (up to 100 U/kg/day).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Defibrotide Prophylaxis

    Standard of Care Immunoprophylaxis + Defibrotide

    Drug: Defibrotide · Drug: Standard of Care

  • Active comparator
    Standard of Care

    Standard of Care Immunoprophylaxis Alone

    Drug: Standard of Care

Interventions

  • 6.25 mg/kg via 2-hour IV infusion every 6 hours

  • DrugStandard of Care

    Administered according to local institutional guidelines, physician preference, and patient need.

06

What researchers measure

Primary outcomes

  1. Cumulative Incidence Percentage of Grade B to D Acute Graft Versus Host Disease (aGvHD) by Day +100 Post-Hematopoietic Stem Cell Transplant (HSCT)

    Cumulative Incidence Percentage of Grade B to D aGvHD was defined using the International Bone Marrow Transplant Registry (IBMTR) Severity Index. Grade B is defined as Skin stage = 2 or Liver stage = 1 to 2 or GI stage = 1 to 2. Grade C is defined as Skin stage = 3 or Liver stage = 3 or GI stage = 3. Grade D is defined as a Skin stage = 4 or Liver stage = 4 or GI stage = 4.

    Time frame: HSCT Day (Day +0 post-HSCT) through Day +100 post-HSCT

Secondary outcomes

  1. Cumulative Incidence Percentage of Grade B to D aGvHD by Day +180 Post-HSCT

    Cumulative Incidence Percentage of Grade B to D aGvHD was defined using the IBMTR Severity Index. Grade B is defined as Skin stage = 2 or Liver stage = 1 to 2 or GI stage = 1 to 2. Grade C is defined as Skin stage = 3 or Liver stage = 3 or GI stage = 3. Grade D is defined as a Skin stage = 4 or Liver stage = 4 or GI stage = 4.

    Time frame: HSCT Day (Day +0 post-HSCT) through Day +180 post-HSCT

  2. Kaplan-Meier Estimate of Grade B to D aGvHD-free Survival by Days +100 and +180 Post-HSCT

    Grade B to D aGvHD was defined using the IBMTR Severity Index. Grade B is defined as Skin stage = 2 or Liver stage = 1 to 2 or GI stage = 1 to 2. Grade C is defined as Skin stage = 3 or Liver stage = 3 or GI stage = 3. Grade D is defined as a Skin stage = 4 or Liver stage = 4 or GI stage = 4.

    Time frame: HSCT Day (Day +0 post-HSCT) through Days +100 and +180 post-HSCT

  3. Cumulative Incidence Percentage of Grade C to D aGvHD by Days +100 and +180 Post-HSCT

    Cumulative Incidence Percentage of Grade C to D aGvHD was defined using the IBMTR Severity Index. Grade C is defined as Skin stage = 3 or Liver stage = 3 or GI stage = 3. Grade D is defined as a Skin stage = 4 or Liver stage = 4 or GI stage = 4.

    Time frame: HSCT Day (Day +0 post-HSCT) through Days +100 and +180 post-HSCT

  4. Cumulative Incidence Percentage of Disease Relapse by Days +100 and +180 Post-HSCT

    Disease relapse was defined by either morphological evidence of acute leukemia or Myelodysplastic syndrome (MDS) consistent with pre-transplant features, documented or not by biopsy. The event was defined as an increase in size of prior sites of disease or evidence of new sites of disease, documented or not by biopsy. Disease relapse was diagnosed when there was morphological or clinical evidence of the following: reappearance of leukemia blast cells in the peripheral blood, or \>5% blasts in the bone marrow (BM), not attributable to another cause (eg, BM regeneration), or the appearance of previous or new dysplastic changes (MDS specific) within the BM, with or without falling donor chimerism, or the development of extramedullary leukemia or leukemic cells in the cerebral spinal fluid, or institution of therapy to treat relapsed disease, including donor lymphocyte infusion.

    Time frame: HSCT Day (Day +0 post-HSCT) through Days +100 and +180 post-HSCT

  5. Cumulative Incidence Percentage of Systemic Steroids for the Treatment of aGvHD +180 Days Post-HSCT

    For each treatment arm, the cumulative incidence rate of systemic steroid use for the treatment of aGvHD by Day +180 post-HSCT will be estimated using the cumulative incidence competing risk estimator. The calculation of the cumulative incidence rates and the stratified Gray's test was carried out using the LIFETEST procedure in SAS version 9.4. If the participant experienced a competing risk event, then the initiation date was used to calculate the time-to-event variable.

    Time frame: HSCT Day (Day +0 post-HSCT) through Day +180 post-HSCT

  6. Change From Baseline to Days +100 and +180 Post-HSCT in the Physical Wellbeing Subscale as Measured by the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Questionnaire Score

    The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) total score is the sum of the FACT physical wellbeing score, the FACT social/family wellbeing score, the FACT emotional wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. The FACT physical wellbeing subscale scores range from a minimum of 0 to a maximum of 28, with higher scores indicating better quality of life. A negative change from baseline indicates a decrease in score.

    Time frame: Baseline through Days +100 and +180 post-HSCT

  7. Change From Baseline to Days +100 and +180 Post-HSCT in the Social/Family Wellbeing Subscale as Measured by the FACT-BMT Questionnaire Score

    The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) total score is the sum of the FACT physical wellbeing score, the FACT social/family wellbeing score, the FACT emotional wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. The FACT social/family wellbeing subscale scores range from a minimum of 0 to a maximum of 28, with higher scores indicating better quality of life. A negative change from baseline indicates a decrease in score.

    Time frame: Baseline through Days +100 and +180 post-HSCT

  8. Change From Baseline to Days +100 and +180 Post-HSCT in the Emotional Wellbeing Subscale as Measured by the FACT-BMT Questionnaire Score

    The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) total score is the sum of the FACT physical wellbeing score, the FACT social/family wellbeing score, the FACT emotional wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. The FACT emotional wellbeing subscale scores range from a minimum of 0 to a maximum of 24, with higher scores indicating better quality of life.

    Time frame: Baseline through Days +100 and +180 post-HSCT

  9. Change From Baseline to Days +100 and +180 Post-HSCT in the Functional Wellbeing Subscale as Measured by the FACT-BMT Questionnaire Score

    The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) total score is the sum of the FACT physical wellbeing score, the FACT social/family wellbeing score, the FACT emotional wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. The FACT functional wellbeing subscale scores range from a minimum of 0 to a maximum of 28, with higher scores indicating better quality of life. A negative change from baseline indicates a decrease in score.

    Time frame: Baseline through Days +100 and +180 post HSCT

  10. Change From Baseline to Days +100 and +180 Post-HSCT in the Bone Marrow Transplantation Subscale (BMTS) as Measured by the FACT-BMT Questionnaire Score

    The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) total score is the sum of the FACT physical wellbeing score, the FACT social/family wellbeing score, the FACT emotional wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. The FACT-BMT subscale scores range from a minimum of 0 to a maximum of 40, with higher scores indicating better quality of life. A negative change from baseline indicates a decrease in score.

    Time frame: Baseline through Days +100 and +180 post-HSCT

  11. Change From Baseline to Days +100 and +180 Post-HSCT in the General (FACT-G) Questionnaire Score

    The FACT-General (FACT-G) is a core component of the FACT-BMT, and includes 4 of the 5 subscales included in the FACT-BMT total score (FACT physical wellbeing score, FACT social/family wellbeing score, FACT emotional wellbeing score, the FACT functional wellbeing score). In line with this similarity, results of the FACT-G exhibited the same pattern as described for the FACT-BMT total score. The FACT-G scores range from a minimParticipants were age ≥16 years at baseline.

    Time frame: Baseline through Days +100 and +180 post-HSCT

  12. Change From Baseline to Days +100 and +180 Post-HSCT in the FACT-BMT Total Score

    The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) total score is the sum of the FACT physical wellbeing score, the FACT social/family wellbeing score, the FACT emotional wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. The FACT-BMT total score range is from a minimum of 0 to a maximum of 148, with higher scores indicating better quality of life. A negative change from baseline indicates a decrease in score.

    Time frame: Baseline through Days +100 and +180 post-HSCT

  13. Change From Baseline to Days +100 and +180 Post-HSCT in the Functional Assessment of Cancer Therapy-Bone Marrow Transplant-Trial Outcomes Index (FACT-BMT-TOI)

    The FACT-BMT-TOI is defined as the sum of the FACT physical wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. Scores range from a minimum of 0 to a maximum of 96, with higher scores indicating better quality of life. A negative change from baseline indicates a decrease in score.

    Time frame: Baseline through Days +100 and +180 post-HSCT

  14. Change From Baseline to Days +100 and +180 Post-HSCT in Participant Reported Outcomes Measured Based on the EQ-5D-5L Index Value for Health States

    The 5-Level EuroQol-5D health questionnaire (EQ-5D-5L) index value, which is country-specific, was only performed for participants in the US. The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Change from the baseline assessment to Days +100 and +180 post-HSCT in the index value was assessed. The index value total range is from a minimum value of -1 to a maximum value of +1. A higher EQ-5D-5L index value represents better quality of life (QoL), thus a positive change in the index value represents improved QoL.

    Time frame: Baseline through Days +100 and +180 post-HSCT

  15. Change From Baseline to Days +100 and +180 Post-HSCT in Participant Reported Outcomes as Measured Based on the EQ Visual Analog Scale (EQ VAS)

    The EQ VAS score at baseline and each of the post-HSCT assessments was summarized and presented using descriptive statistics. A higher EQ VAS score represents better QoL. For each of the post-HSCT assessments, change between baseline and that assessment in the EQ VAS score was calculated similarly to the EQ-5D-5L index value for a specific participant and was summarized and presented using descriptive statistics. The score ranges from a minimum of 0 and a maximum of 100. A negative change in the score indicates a decrease in quality of life.

    Time frame: Baseline through Days +100 and +180 post-HSCT

  16. Change From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Mobility Dimension for Participants With Age >=16 Years

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +100 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

    Time frame: Baseline through Day +100 post-HSCT

  17. Change From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Mobility Dimension for Participants With Age >=16 Years

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +180 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

    Time frame: Baseline through Day +180 post-HSCT

  18. Change From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Pain/Discomfort Dimension for Participants With Age >=16 Years

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Days +100 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

    Time frame: Baseline through Day +100 post-HSCT

  19. Change From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Pain/Discomfort Dimension for Participants With Age >=16 Years

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +180 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

    Time frame: Baseline through Day +180 post-HSCT

  20. Change From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Self-Care Dimension for Participants With Age >=16 Years

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +100 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

    Time frame: Baseline through Day +100 post-HSCT

  21. Change From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Self-Care Dimension for Participants With Age >=16 Years

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +180 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

    Time frame: Baseline through Day +180 post-HSCT

  22. Change From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Usual Activities Dimension for Participants With Age >=16 Years

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +100 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

    Time frame: Baseline through Day +100 post-HSCT

  23. Change From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Usual Activities Dimension for Participants With Age >=16 Years

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +180 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

    Time frame: Baseline through Day +180 post-HSCT

  24. Change From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Anxiety/Depression Dimension for Participants With Age >=16 Years

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +100 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

    Time frame: Baseline through Day +100 post-HSCT

  25. Change From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Anxiety/Depression Dimension for Participants With Age >=16 Years

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +180 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

    Time frame: Baseline through Day +180 post-HSCT

07

Results

Posted Aug 18, 2021

Participant flow

Participant flow — Overall Study
MilestoneDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Started7973
Completed5659
Not completed2314
Withdrew: Relapse of hematologic disease10
Withdrew: Death107
Withdrew: Hepatic candidosis10
Withdrew: Adverse event, serious fatal02
Withdrew: Consent withdrawn by participant33
Withdrew: Disease relapse20
Withdrew: Physician decision11
Withdrew: Relapse of disease new transplant performed10
Withdrew: Problems with donor and diagnosis of early relapse10
Withdrew: Early termination, did not proceed to transplant10
Withdrew: Adverse event, non-fatal10
Withdrew: Patient relapsed and did not proceed to transplant01
Withdrew: Patient was not eligible10

Outcome measures

PrimaryCumulative Incidence Percentage of Grade B to D Acute Graft Versus Host Disease (aGvHD) by Day +100 Post-Hematopoietic Stem Cell Transplant (HSCT)

Cumulative Incidence Percentage of Grade B to D aGvHD was defined using the International Bone Marrow Transplant Registry (IBMTR) Severity Index. Grade B is defined as Skin stage = 2 or Liver stage = 1 to 2 or GI stage = 1 to 2. Grade C is defined as Skin stage = 3 or Liver stage = 3 or GI stage = 3. Grade D is defined as a Skin stage = 4 or Liver stage = 4 or GI stage = 4.

Time frame:
HSCT Day (Day +0 post-HSCT) through Day +100 post-HSCT
Reported as:
Number · cumulative incidence percentage
Cumulative Incidence Percentage of Grade B to D Acute Graft Versus Host Disease (aGvHD) by Day +100 Post-Hematopoietic Stem Cell Transplant (HSCT)
cumulative incidence percentageDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Cumulative Incidence Percentage of Grade B to D Acute Graft Versus Host Disease (aGvHD) by Day +100 Post-Hematopoietic Stem Cell Transplant (HSCT)38.447.1
SecondaryCumulative Incidence Percentage of Grade B to D aGvHD by Day +180 Post-HSCT

Cumulative Incidence Percentage of Grade B to D aGvHD was defined using the IBMTR Severity Index. Grade B is defined as Skin stage = 2 or Liver stage = 1 to 2 or GI stage = 1 to 2. Grade C is defined as Skin stage = 3 or Liver stage = 3 or GI stage = 3. Grade D is defined as a Skin stage = 4 or Liver stage = 4 or GI stage = 4.

Time frame:
HSCT Day (Day +0 post-HSCT) through Day +180 post-HSCT
Reported as:
Number · cumulative incidence percentage
Cumulative Incidence Percentage of Grade B to D aGvHD by Day +180 Post-HSCT
cumulative incidence percentageDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Cumulative Incidence Percentage of Grade B to D aGvHD by Day +180 Post-HSCT50.651.6
SecondaryKaplan-Meier Estimate of Grade B to D aGvHD-free Survival by Days +100 and +180 Post-HSCT

Grade B to D aGvHD was defined using the IBMTR Severity Index. Grade B is defined as Skin stage = 2 or Liver stage = 1 to 2 or GI stage = 1 to 2. Grade C is defined as Skin stage = 3 or Liver stage = 3 or GI stage = 3. Grade D is defined as a Skin stage = 4 or Liver stage = 4 or GI stage = 4.

Time frame:
HSCT Day (Day +0 post-HSCT) through Days +100 and +180 post-HSCT
Reported as:
Number · percentage of participants
Kaplan-Meier Estimate of Grade B to D aGvHD-free Survival by Days +100 and +180 Post-HSCT
percentage of participantsDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Day +100 post-HSCT60.351.4
Day +180 post-HSCT45.142.6
SecondaryCumulative Incidence Percentage of Grade C to D aGvHD by Days +100 and +180 Post-HSCT

Cumulative Incidence Percentage of Grade C to D aGvHD was defined using the IBMTR Severity Index. Grade C is defined as Skin stage = 3 or Liver stage = 3 or GI stage = 3. Grade D is defined as a Skin stage = 4 or Liver stage = 4 or GI stage = 4.

Time frame:
HSCT Day (Day +0 post-HSCT) through Days +100 and +180 post-HSCT
Reported as:
Number · cumulative incidence percentage
Cumulative Incidence Percentage of Grade C to D aGvHD by Days +100 and +180 Post-HSCT
cumulative incidence percentageDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Day +100 post-HSCT16.521.5
Day +180 post-HSCT22.725.9
SecondaryCumulative Incidence Percentage of Disease Relapse by Days +100 and +180 Post-HSCT

Disease relapse was defined by either morphological evidence of acute leukemia or Myelodysplastic syndrome (MDS) consistent with pre-transplant features, documented or not by biopsy. The event was defined as an increase in size of prior sites of disease or evidence of new sites of disease, documented or not by biopsy. Disease relapse was diagnosed when there was morphological or clinical evidence of the following: reappearance of leukemia blast cells in the peripheral blood, or \>5% blasts in the bone marrow (BM), not attributable to another cause (eg, BM regeneration), or the appearance of previous or new dysplastic changes (MDS specific) within the BM, with or without falling donor chimerism, or the development of extramedullary leukemia or leukemic cells in the cerebral spinal fluid, or institution of therapy to treat relapsed disease, including donor lymphocyte infusion.

Time frame:
HSCT Day (Day +0 post-HSCT) through Days +100 and +180 post-HSCT
Reported as:
Number · cumulative incidence percentage
Cumulative Incidence Percentage of Disease Relapse by Days +100 and +180 Post-HSCT
cumulative incidence percentageDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Day +100 post-HSCT11.04.3
Day +180 post-HSCT16.85.8
SecondaryCumulative Incidence Percentage of Systemic Steroids for the Treatment of aGvHD +180 Days Post-HSCT

For each treatment arm, the cumulative incidence rate of systemic steroid use for the treatment of aGvHD by Day +180 post-HSCT will be estimated using the cumulative incidence competing risk estimator. The calculation of the cumulative incidence rates and the stratified Gray's test was carried out using the LIFETEST procedure in SAS version 9.4. If the participant experienced a competing risk event, then the initiation date was used to calculate the time-to-event variable.

Time frame:
HSCT Day (Day +0 post-HSCT) through Day +180 post-HSCT
Reported as:
Number · cumulative incidence percentage
Cumulative Incidence Percentage of Systemic Steroids for the Treatment of aGvHD +180 Days Post-HSCT
cumulative incidence percentageDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Cumulative Incidence Percentage of Systemic Steroids for the Treatment of aGvHD +180 Days Post-HSCT38.228.6
SecondaryChange From Baseline to Days +100 and +180 Post-HSCT in the Physical Wellbeing Subscale as Measured by the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Questionnaire Score

The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) total score is the sum of the FACT physical wellbeing score, the FACT social/family wellbeing score, the FACT emotional wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. The FACT physical wellbeing subscale scores range from a minimum of 0 to a maximum of 28, with higher scores indicating better quality of life. A negative change from baseline indicates a decrease in score.

Time frame:
Baseline through Days +100 and +180 post-HSCT
Reported as:
Mean · unit on a scale
Change From Baseline to Days +100 and +180 Post-HSCT in the Physical Wellbeing Subscale as Measured by the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Questionnaire Score
unit on a scaleDefibrotide ProphylaxisStandard of Care Immunoprohylaxis
Change from Baseline to Day +100 post-HSCT-1.25 ± 5.069-1.41 ± 6.371
Change from Baseline to Day +180 post-HSCT-1.55 ± 5.230-1.54 ± 5.717
SecondaryChange From Baseline to Days +100 and +180 Post-HSCT in the Social/Family Wellbeing Subscale as Measured by the FACT-BMT Questionnaire Score

The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) total score is the sum of the FACT physical wellbeing score, the FACT social/family wellbeing score, the FACT emotional wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. The FACT social/family wellbeing subscale scores range from a minimum of 0 to a maximum of 28, with higher scores indicating better quality of life. A negative change from baseline indicates a decrease in score.

Time frame:
Baseline through Days +100 and +180 post-HSCT
Reported as:
Mean · unit on a scale
Change From Baseline to Days +100 and +180 Post-HSCT in the Social/Family Wellbeing Subscale as Measured by the FACT-BMT Questionnaire Score
unit on a scaleDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Change from Baseline to Day +100 post-HSCT-0.56 ± 3.488-0.29 ± 5.716
Change from Baseline to Day +180 post-HSCT-0.78 ± 4.085-1.34 ± 3.380
SecondaryChange From Baseline to Days +100 and +180 Post-HSCT in the Emotional Wellbeing Subscale as Measured by the FACT-BMT Questionnaire Score

The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) total score is the sum of the FACT physical wellbeing score, the FACT social/family wellbeing score, the FACT emotional wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. The FACT emotional wellbeing subscale scores range from a minimum of 0 to a maximum of 24, with higher scores indicating better quality of life.

Time frame:
Baseline through Days +100 and +180 post-HSCT
Reported as:
Mean · unit on a scale
Change From Baseline to Days +100 and +180 Post-HSCT in the Emotional Wellbeing Subscale as Measured by the FACT-BMT Questionnaire Score
unit on a scaleDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Change from Baseline to Day +100 post-HSCT1.47 ± 4.9101.47 ± 3.659
Change from Baseline to Day +180 post-HSCT0.79 ± 4.6831.53 ± 3.458
SecondaryChange From Baseline to Days +100 and +180 Post-HSCT in the Functional Wellbeing Subscale as Measured by the FACT-BMT Questionnaire Score

The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) total score is the sum of the FACT physical wellbeing score, the FACT social/family wellbeing score, the FACT emotional wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. The FACT functional wellbeing subscale scores range from a minimum of 0 to a maximum of 28, with higher scores indicating better quality of life. A negative change from baseline indicates a decrease in score.

Time frame:
Baseline through Days +100 and +180 post HSCT
Reported as:
Mean · unit on a scale
Change From Baseline to Days +100 and +180 Post-HSCT in the Functional Wellbeing Subscale as Measured by the FACT-BMT Questionnaire Score
unit on a scaleDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Change from Baseline to Day +100 post-HSCT-1.71 ± 5.622-2.11 ± 5.962
Change from Baseline to Day +180 post-HSCT-2.21 ± 7.241-0.95 ± 6.627
SecondaryChange From Baseline to Days +100 and +180 Post-HSCT in the Bone Marrow Transplantation Subscale (BMTS) as Measured by the FACT-BMT Questionnaire Score

The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) total score is the sum of the FACT physical wellbeing score, the FACT social/family wellbeing score, the FACT emotional wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. The FACT-BMT subscale scores range from a minimum of 0 to a maximum of 40, with higher scores indicating better quality of life. A negative change from baseline indicates a decrease in score.

Time frame:
Baseline through Days +100 and +180 post-HSCT
Reported as:
Mean · unit on a scale
Change From Baseline to Days +100 and +180 Post-HSCT in the Bone Marrow Transplantation Subscale (BMTS) as Measured by the FACT-BMT Questionnaire Score
unit on a scaleDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Change from Baseline to Day +100 post-HSCT-0.88 ± 5.484-2.14 ± 5.900
Change from Baseline to Day +180 post-HSCT-2.33 ± 7.037-1.01 ± 6.173
SecondaryChange From Baseline to Days +100 and +180 Post-HSCT in the General (FACT-G) Questionnaire Score

The FACT-General (FACT-G) is a core component of the FACT-BMT, and includes 4 of the 5 subscales included in the FACT-BMT total score (FACT physical wellbeing score, FACT social/family wellbeing score, FACT emotional wellbeing score, the FACT functional wellbeing score). In line with this similarity, results of the FACT-G exhibited the same pattern as described for the FACT-BMT total score. The FACT-G scores range from a minimParticipants were age ≥16 years at baseline.

Time frame:
Baseline through Days +100 and +180 post-HSCT
Reported as:
Mean · unit on a scale
Change From Baseline to Days +100 and +180 Post-HSCT in the General (FACT-G) Questionnaire Score
unit on a scaleDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Change from Baseline to Day +100 post-HSCT-2.38 ± 12.623-1.74 ± 15.623
Change from Baseline to Day +180 post-HSCT-4.03 ± 15.366-1.33 ± 13.613
SecondaryChange From Baseline to Days +100 and +180 Post-HSCT in the FACT-BMT Total Score

The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) total score is the sum of the FACT physical wellbeing score, the FACT social/family wellbeing score, the FACT emotional wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. The FACT-BMT total score range is from a minimum of 0 to a maximum of 148, with higher scores indicating better quality of life. A negative change from baseline indicates a decrease in score.

Time frame:
Baseline through Days +100 and +180 post-HSCT
Reported as:
Mean · unit on a scale
Change From Baseline to Days +100 and +180 Post-HSCT in the FACT-BMT Total Score
unit on a scaleDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Change from Baseline to Day +100 post-HSCT-3.24 ± 16.036-3.70 ± 19.854
Change from Baseline to Day +180 post-HSCT-6.38 ± 21.358-2.83 ± 18.079
SecondaryChange From Baseline to Days +100 and +180 Post-HSCT in the Functional Assessment of Cancer Therapy-Bone Marrow Transplant-Trial Outcomes Index (FACT-BMT-TOI)

The FACT-BMT-TOI is defined as the sum of the FACT physical wellbeing score, the FACT functional wellbeing score, and the FACT-BMT subscale. Scores range from a minimum of 0 to a maximum of 96, with higher scores indicating better quality of life. A negative change from baseline indicates a decrease in score.

Time frame:
Baseline through Days +100 and +180 post-HSCT
Reported as:
Mean · unit on a scale
Change From Baseline to Days +100 and +180 Post-HSCT in the Functional Assessment of Cancer Therapy-Bone Marrow Transplant-Trial Outcomes Index (FACT-BMT-TOI)
unit on a scaleDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Change from Baseline to Day +100 post-HSCT-3.88 ± 13.110-5.24 ± 15.575
Change from Baseline to Day +180 post-HSCT-6.99 ± 17.393-3.33 ± 14.922
SecondaryChange From Baseline to Days +100 and +180 Post-HSCT in Participant Reported Outcomes Measured Based on the EQ-5D-5L Index Value for Health States

The 5-Level EuroQol-5D health questionnaire (EQ-5D-5L) index value, which is country-specific, was only performed for participants in the US. The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Change from the baseline assessment to Days +100 and +180 post-HSCT in the index value was assessed. The index value total range is from a minimum value of -1 to a maximum value of +1. A higher EQ-5D-5L index value represents better quality of life (QoL), thus a positive change in the index value represents improved QoL.

Time frame:
Baseline through Days +100 and +180 post-HSCT
Reported as:
Mean · unit on a scale
Change From Baseline to Days +100 and +180 Post-HSCT in Participant Reported Outcomes Measured Based on the EQ-5D-5L Index Value for Health States
unit on a scaleDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Change from Baseline to Day +100 post-HSCT0.02 ± 0.092-0.01 ± 0.101
Change from Baseline to Day +180 post-HSCT0.02 ± 0.078-0.01 ± 0.121
SecondaryChange From Baseline to Days +100 and +180 Post-HSCT in Participant Reported Outcomes as Measured Based on the EQ Visual Analog Scale (EQ VAS)

The EQ VAS score at baseline and each of the post-HSCT assessments was summarized and presented using descriptive statistics. A higher EQ VAS score represents better QoL. For each of the post-HSCT assessments, change between baseline and that assessment in the EQ VAS score was calculated similarly to the EQ-5D-5L index value for a specific participant and was summarized and presented using descriptive statistics. The score ranges from a minimum of 0 and a maximum of 100. A negative change in the score indicates a decrease in quality of life.

Time frame:
Baseline through Days +100 and +180 post-HSCT
Reported as:
Mean · unit on a scale
Change From Baseline to Days +100 and +180 Post-HSCT in Participant Reported Outcomes as Measured Based on the EQ Visual Analog Scale (EQ VAS)
unit on a scaleDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Change from Baseline to Day +100 post-HSCT6.03 ± 20.5992.70 ± 15.004
Change from Baseline to Day +180 post-HSCT2.24 ± 29.023-0.90 ± 21.530
SecondaryChange From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Mobility Dimension for Participants With Age >=16 Years

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +100 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

Time frame:
Baseline through Day +100 post-HSCT
Reported as:
Count of participants · Participants
Change From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Mobility Dimension for Participants With Age >=16 Years
ParticipantsDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Condition improved34
Condition unchanged3128
Condition deteriorated815
Unknown1915
SecondaryChange From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Mobility Dimension for Participants With Age >=16 Years

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +180 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

Time frame:
Baseline through Day +180 post-HSCT
Reported as:
Count of participants · Participants
Change From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Mobility Dimension for Participants With Age >=16 Years
ParticipantsDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Condition improved33
Condition unchanged2625
Condition deteriorated1114
Unknown1719
SecondaryChange From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Pain/Discomfort Dimension for Participants With Age >=16 Years

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Days +100 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

Time frame:
Baseline through Day +100 post-HSCT
Reported as:
Count of participants · Participants
Change From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Pain/Discomfort Dimension for Participants With Age >=16 Years
ParticipantsDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Condition improved109
Condition unchanged1820
Condition deteriorated1418
Unknown1915
SecondaryChange From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Pain/Discomfort Dimension for Participants With Age >=16 Years

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +180 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

Time frame:
Baseline through Day +180 post-HSCT
Reported as:
Count of participants · Participants
Change From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Pain/Discomfort Dimension for Participants With Age >=16 Years
ParticipantsDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Condition improved68
Condition unchanged2320
Condition deteriorated1114
Unknown1719
SecondaryChange From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Self-Care Dimension for Participants With Age >=16 Years

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +100 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

Time frame:
Baseline through Day +100 post-HSCT
Reported as:
Count of participants · Participants
Change From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Self-Care Dimension for Participants With Age >=16 Years
ParticipantsDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Condition improved10
Condition unchanged3437
Condition deteriorated710
Unknown1915
SecondaryChange From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Self-Care Dimension for Participants With Age >=16 Years

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +180 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

Time frame:
Baseline through Day +180 post-HSCT
Reported as:
Count of participants · Participants
Change From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Self-Care Dimension for Participants With Age >=16 Years
ParticipantsDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Condition improved21
Condition unchanged3431
Condition deteriorated410
Unknown1719
SecondaryChange From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Usual Activities Dimension for Participants With Age >=16 Years

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +100 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

Time frame:
Baseline through Day +100 post-HSCT
Reported as:
Count of participants · Participants
Change From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Usual Activities Dimension for Participants With Age >=16 Years
ParticipantsDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Condition improved87
Condition unchanged2122
Condition deteriorated1318
Unknown1915
SecondaryChange From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Usual Activities Dimension for Participants With Age >=16 Years

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +180 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

Time frame:
Baseline through Day +180 post-HSCT
Reported as:
Count of participants · Participants
Change From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Usual Activities Dimension for Participants With Age >=16 Years
ParticipantsDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Condition improved105
Condition unchanged1619
Condition deteriorated1418
Unknown1719
SecondaryChange From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Anxiety/Depression Dimension for Participants With Age >=16 Years

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +100 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

Time frame:
Baseline through Day +100 post-HSCT
Reported as:
Count of participants · Participants
Change From Baseline to Day +100 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Anxiety/Depression Dimension for Participants With Age >=16 Years
ParticipantsDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Condition improved710
Condition unchanged2730
Condition deteriorated87
Unknown1915
SecondaryChange From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Anxiety/Depression Dimension for Participants With Age >=16 Years

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of the 5 dimensions based on the descriptive system of the EQ-5D-5L, the numbers of participants for all categories (the 5 levels of reported problems) were assessed. For Day +180 Post-HSCT change between baseline in each dimension will be categorized as follows for a specific participant: Condition improved, if the reported level of problem is lower at that assessment than at baseline; Condition unchanged, if the reported level of problem remains the same; Condition deteriorated, if the reported level of problem is higher at that assessment than at baseline; Unknown, if the reported level of problem is not completed or missing either at baseline or at that assessment.

Time frame:
Baseline through Day +180 post-HSCT
Reported as:
Count of participants · Participants
Change From Baseline to Day +180 Post-HSCT in 5-Level European Quality of Life (EQ-5D-5L) Anxiety/Depression Dimension for Participants With Age >=16 Years
ParticipantsDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Condition improved812
Condition unchanged2123
Condition deteriorated116
Unknown1720

Adverse events

Collected over All Adverse Events (AEs) and Serious Adverse Events (SAEs) were reported from the time of signed informed consent form (ICF) and were recorded up to Day +63 post-HSCT. SAEs considered by the investigator to be related to study drug or study procedures were reported up to Day +180 post-HSCT.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Defibrotide Prophylaxis10/74 (13.5%)31/74 (41.9%)74/74 (100%)
Standard of Care Immunoprophylaxis9/70 (12.9%)31/70 (44.3%)70/70 (100%)
Most frequent serious events
Showing 10 of 82
Most frequent serious events
EventDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
Acute graft versus host disease in skinImmune system disorders1/744/70
Acute graft versus host diseaseImmune system disorders4/741/70
DyspnoeaRespiratory, thoracic and mediastinal disorders3/740/70
DiarrhoeaGastrointestinal disorders3/742/70
Acute kidney injuryRenal and urinary disorders3/742/70
Venoocclusive liver diseaseHepatobiliary disorders0/742/70
SepsisInfections and infestations0/742/70
Septic shockInfections and infestations0/742/70
Acute graft versus host disease in intestineImmune system disorders2/741/70
NauseaGastrointestinal disorders2/741/70
Most frequent other events
Showing 10 of 122
Most frequent other events
EventDefibrotide ProphylaxisStandard of Care Immunoprophylaxis
DiarrhoeaGastrointestinal disorders47/7453/70
NauseaGastrointestinal disorders56/7449/70
StomatitisGastrointestinal disorders42/7436/70
VomitingGastrointestinal disorders39/7438/70
HypomagnesaemiaMetabolism and nutrition disorders30/7435/70
AnaemiaBlood and lymphatic system disorders27/7430/70
Decreased appetiteMetabolism and nutrition disorders30/7430/70
HeadacheNervous system disorders31/7423/70
HypertensionVascular disorders25/7429/70
ConstipationGastrointestinal disorders28/7429/70

Baseline characteristics

Baseline characteristics were assessed using the Intent-to-Treat (ITT) Analysis Set.

Age, Continuous
Age, Continuous(years)Defibrotide ProphylaxisStandard of Care ImmunoprophylaxisTotal
Mean50.54 ± 16.95251.09 ± 16.62150.80 ± 16.741
Sex: Female, Male
Sex: Female, Male(Participants)Defibrotide ProphylaxisStandard of Care ImmunoprophylaxisTotal
Female383775
Male413677
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Defibrotide ProphylaxisStandard of Care ImmunoprophylaxisTotal
Hispanic or Latino112
Not Hispanic or Latino6763130
Unknown or Not Reported11920
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Defibrotide ProphylaxisStandard of Care ImmunoprophylaxisTotal
American Indian or Alaska Native000
Asian145
Native Hawaiian or Other Pacific Islander000
Black or African American011
White6663129
More than one race000
Unknown or Not Reported12517
08

Study locations

62 sites
  • USC Norris Cancer Center
    Los Angeles, California 90033, United States
  • Mattel Children's Hospital UCLA
    Los Angeles, California 90095, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • University of California, San Francisco Medical Center
    San Francisco, California 94143, United States
  • Mayo Clinic Jacksonville - PPDS
    Jacksonville, Florida 32224, United States
  • Blood & Marrow Transplant Center
    Orlando, Florida 32804, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • University of Kansas Medical Center
    Westwood, Kansas 66205, United States
  • James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Montefiore Einstein Cancer Center
    Bronx, New York 10467, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Penn State Milton S Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • MUSC-Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • VA Puget Sound Health Care System
    Seattle, Washington 98108, United States
  • West Virginia University Hospital
    Morgantown, West Virginia 26506, United States
  • Universitätsklinikum Innsbruck
    Innsbruck, 6020, Austria
  • Ordensklinikum Linz, Krankenhaus der Elisabethinen GmbH
    Linz, 4020, Austria
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Specialized Hospital for Active Treatment of Haematological Diseases - Sofia
    Sofia, 1756, Bulgaria
  • Hôpital Maisonneuve-Rosemont
    Montreal, H1T 2M4, Canada
  • Sainte Justine Hospital
    Montreal, H3T 1C5, Canada
  • McGill University Health Center
    Montreal, H4A 3J1, Canada
  • Klinichki Bolnicki Centar Zagreb
    Zagreb, 10000, Croatia
  • Hospital d Instructions des Armees Percy
    Clamart, 92141, France
  • CHRU Lille
    Lille, 59037, France
  • Institut Universitaire du Cancer de Toulouse - Oncopole
    Toulouse, 31059, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Helios Klinikum Berlin Buch
    Berlin, 13125, Germany
  • Medizinische Universitätsklinik Knappschaftskrankenhaus
    Bochum, 44892, Germany
  • Klinikum Frankfurt (Oder) GmbH
    Brandenburg, 15236, Germany
  • Universitätsklinikum Carl Gustav Carus an der TU Dresden
    Dresden, 01307, Germany
  • University Medicine Göttingen Germany
    Göttingen, 37075, Germany
  • Universitaetsklinikum Halle (Saale)
    Halle, 06120, Germany
  • Uniklinik Köln
    Köln, 50937, Germany
  • Universitatsklinikum Leipzig
    Leipzig, 04103, Germany
  • Klinikum Mannheim Universitätsklinikum gGmbH
    Mannheim, 68167, Germany
  • Klinikum rechts der Isar der Technischen Universität München
    Munchen, 81675, Germany
  • Klinikum der Universitat Regensburg
    Regensburg, 93053, Germany
  • Attikon University General Hospital
    Athens, 12462, Greece
  • University General Hospital of Patras
    Patras, 26500, Greece
  • ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda
    Milano, 20162, Italy
  • Azienda Ospedaliero Universitaria di Parma
    Parma, 41236, Italy
  • Ospedale Pediatrico Bambino Gesù
    Roma, 00165, Italy
  • Centrum Onkologii im. Marii Sklodowskiej-Curie
    Warsaw, 00-001, Poland
  • Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku
    Wrocław, 53-439, Poland
  • Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.
    Lisboa, 1099, Portugal
  • Hospital Universitario Marques de Valdecilla
    Coruña, 15006, Spain
  • Hospital de Gran Canaria Doctor Negrin
    Las Palmas De Gran Canaria, 35010, Spain
  • Hospital Universitario Puerta de Hierro - Majadahonda
    Madrid, 28222, Spain
  • Complejo Asistencial Universitario de Salamanca - H. Clinico
    Salamanca, 37007, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 41013, Spain
  • Birmingham Heartlands Hospital
    Birmingham, B9 5SS, United Kingdom
  • St James University Hospital
    Leeds, LS9 7TF, United Kingdom
  • St. James University Hospital
    Leeds, LS9 7TF, United Kingdom
  • Leicester Royal Infirmary
    Leicester, LE1 5WW, United Kingdom
  • Manchester Royal Infirmary
    Manchester, LE1 5WW, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in May 2020, 26 months.

Results were first posted in Aug 2021, 1 year 3 months after primary completion.

Of 103 phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 87. This study's 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2017
First posted
Nov 13, 2017
StartActual
Feb 21, 2018
Primary completionActual
May 12, 2020
CompletionActual
May 12, 2020
Results first posted
Aug 18, 2021
Last update
Aug 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03339297
Responsible party
Sponsor
First posted
Nov 13, 2017
Start date
Feb 21, 2018
Primary completion
May 12, 2020
Completion
May 12, 2020
Results posted
Aug 18, 2021
Last update
Aug 18, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Defibrotide

Start the discussion